Ulixertinib, a first-in-class ERK inhibitor, is currently being investigated in an early Phase I study (NCT05804227) enrolling adolescents and adults with MAPK-activated gliomas, including NF1-associated low-grade gliomas. The gene discussed is NF1; the disease is glioma.